TrialThe Lancet. Infectious diseases2018

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.

James G Hakim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.